Internet Drug
Pharmaceutical News & Information; Updated Daily Since 1998

Drug Coupons Database
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

4/29 Industry Pundit Thinks FDA Will Overrule Panel on Eteplirsen
Sarepta Can Win Speedy FDA Drug Approval .... If Woodcock agreed with all the bad things said about eteplirsen on Monday night, if she had no plans to overrule or cast aside the recommendations against approval, why did she go out of her way to meet with DMD boys and their families immediately after the meeting ended? .... The Street (Adam Feuerstein)

4/29 ESRX Will Swat Down Price Hikes Immediately
Valeant-Style Price Hikes Targeted for Review by Drug Plan .... Express Scripts is starting a new program designed to respond rapidly to price spikes on old drugs, making it easier to steer patients to cheaper alternatives when a medicine unexpectedly soars in price .... Bloomberg

4/29 Bidding Opens for Medivation
Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation .... Sanofi's non-binding proposal is to buy Medivation for $52.50 per share in cash, representing a roughly 36 percent premium over Medivation's stock price one month prior .... Reuters

4/29 Abbvie Buys Stemcentrx
AbbVie forges deeper into cancer, as clock ticks for Humira .... The suburban Chicago drugmaker will buy privately held Stemcentrx and its experimental treatment for small cell lung cancer, which accounts for about 10 percent to 15 percent of all lung cancers and is notoriously difficult to treat .... Reuters

4/29 Explosive New Technologies — Liquid Biopsies, Gene Tests — Draw Regulators
There's a new sheriff in town in Silicon Valley — the FDA .... As a tidal wave of new health-related gadgets, apps and tests hits the market, the Food and Drug Administration, the Federal Trade Commission and other enforcement agencies are showing up in Silicon Valley like they've never done before. .... Washington Post

4/29 Sovaldi and Harvoni Sales Flat; But Gilead Has $26 Billion in the Bank for New Pipeline
Gilead's Profit, Hepatitis C Drugs Sales Miss Estimates .... While the drugs have been among the fastest-selling medications of all time, AbbVie and Merck & Co. now offer similar products. Gilead has said it expects U.S. sales of its hepatitis pills to be flat this year .... Bloomberg

4/29 Public Citizen Mad About How FDA Redacts Public Resumes of Advisors
FDA sued for hiding too much info about its expert panel members .... A consumer advocacy group has gone to court to force the agency to disclose more information about the people whose opinions help determine the fate of numerous drugs and devices .... Pharmalot

4/29 SGLT2s Overtaking DPP4s
Following positive outcomes data, a new diabetes class is on the rise .... New patient growth for drugs in the category is in the single digits year-to-date — but total prescriptions are up over 30% .... MM&M

4/29 Xtampza, Abuse-Resistant Form of Oxycodone
FDA Approves New Version of Oxycodone .... Xtampza is made by Massachusetts-based Collegium Pharmaceutical with proprietary technology that combines oxycodone with fatty acid and waxes to form small spherical beads that are placed inside the capsule. The beads are designed to resist breaking, crushing, chewing, dissolving and melting .... Pain News Network

4/29 Takeover in Heart Devices Market
Abbott to Acquire St. Jude Medical for $25 Billion .... Abbott and St. Jude Medical will capture a larger position across the market for cardiovascular devices .... NY Times

4/29 Average Monthly Cost of Oral Cancer Drugs Launched in 2000: $1,869. In 2014: $11,325
Spike in Cost of Certain Oral Cancer Drugs Puts Squeeze on Patients .... These kinds of medications have become more popular since 2000, with 32 therapies introduced between 2000 to 2014. .... ABC News

4/29 Internet Drug News Fast Takes:
Patients' top complaint? It isn't doctors or nurses, study finds
Advisory Board Daily Briefing
Drug Overdose Deaths Leading to More Organ Donors
US News
Acadia drug approval could clear way for Axovant dementia therapy
What Pharma's Are Doing on Periscope — Update on the Landscape
Eye on FDA
Aurobindo to move U.S. HQ, manufacturing to North Carolina
Fierce Pharma

4/28 Whistleblowers (One a Repeat) Win $98 Million in Protonix Settlement
Pfizer to Pay $784.6 Million to Resolve Drug Discount Case .... Pfizer agreed to pay $784.6 million to resolve a 14-year-old lawsuit claiming its Wyeth unit overcharged the government by hiding the discounts it was giving hospitals for drugs used to treat acid-related damage to the esophagus .... Bloomberg

4/28 GSK Turns a Corner
Glaxo Profit Rises for First Time Since 2013, Tops Estimates .... GlaxoSmithKline reported its first increase in quarterly profit since 2013, as demand for its vaccines and new drugs helped offset declines in the sales of its blockbuster Advair. .... Bloomberg (includes video with CEO Andrew Witty)

4/28 "The price is never the price, unless you're a cash-paying customer" (Adam Fein) — The New York Times Explains High Drug Costs
The Complex Math Behind Spiraling Prescription Drug Prices .... Although list prices for drugs rose about 12 percent in 2015, net prices — what insurers and employers actually paid — grew only about 2.8 percent, the lowest rate in years, according to IMS Health .... NY Times

4/28 Addyi Creator's Latest Project: Date Rape Drug-Detecting Fingernail Polish
The Woman Behind the 'Female Viagra' Has a New Venture .... Called The Pink Ceiling — a fitting name, given Whitehead's signature hot pink lipstick and clothing — the new company is something of a cross between a VC fund, an incubator, and a consulting firm. Whitehead says that the company will partner with startups that provide products or services to women, helping the fledgling businesses come to market and scale .... Fortune

4/28 $3 Billion in Mobile Pharma Ads in 2015
Mobile ad spending up, but pharma's share remains small .... Retail, finance and cars are still the biggest overall spenders in digital media, the IAB report found, accounting for 22%, 13% and 13% of the total spend respectively. The pharma and healthcare category was eighth on the list of IAB industry spenders, contributing 5% of the total digital spend .... Fierce Pharma

4/28 Canadian Company Offers a Deal on Xtandi
Small company offers Medicare cheap version of pricey cancer drug .... Biolyse Pharma maintains that it can supply a version of Xtandi for $3 per 40-milligram tablet, compared with the $69.41 that Medicare paid in 2014 .... Pharmalot

4/28 Second US Biosimilar Faces Acceptance Hurdles
Why Inflectra may face greater challenges than Zarxio in winning over US docs .... Anti-TNG drugs like Remicade are generally used to treat chronic diseases over the course of a lifetime. Neupogen, and by extension Zarxio, is used only for a limited period of time .... BioPharmaDive

4/28 Valeant Officials Blasted at Senate
Ackman, Valeant Offers Apologies, Concessions at Drug Hearing .... Valeant Pharmaceuticals's outgoing chief executive, Mike Pearson, and billionaire investor Bill Ackman offered apologies and concessions to U.S. lawmakers at a Senate hearing on the price of drugs .... Bloomberg

4/28 FDA Pushes PDUFA Date Back for Hep B Vaccine
Dynavax further delayed as FDA says wait until Christmas for hep B vax decision .... Dynavax hopes to have an edge with over the marketed treatments as its vaccine as it is injected in two doses over one-month--whereas its rivals are administered in three doses over a six-month schedule .... Fierce Biotech

4/28 New Designations for Ilaris
Novartis' Ilaris awarded three breakthrough badges in the US .... The three conditions for which Ilaris is being reviewed are Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TRAPS) and Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) not adequately controlled with colchicine .... Pharma Times

4/28 Internet Drug News Fast Takes:
FDA Says "No" to Single-Tablet Combination of Aripiprazole and Ingestible Sensor
PT Community
With more cash, we can eliminate malaria within our lifetime: ex-WHO official
Advocates hold NYC protest over price of pneumonia vaccine
The 7 Deadliest Emergency General Surgeries
HealthDay News
That Surgery Might Cost You A Lot Less In Another Town
Working longer may lead to a longer life, new research shows
Oregon State University

4/27 Steep Price Hikes Continue in 2016
Drug Prices Keep Rising Despite Intense Criticism .... Drug makers have raised prices on brand-name drugs by double-digit percentages since the start of the year, according to interviews with executives at Express Scripts and CVS Caremark, two major drug-benefit managers .... NY Times

4/27 Cabometyx Approved for Kidney Cancer
Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin! .... Cabometyx produced a hazard ratio of 0.66 compared to Afinitor, which corresponds to a 34% reduction in the rate of death. Opdivo produced a hazard ratio of 0.73 compared to Afinitor, a 27% reduction in the rate of death .... Motley Fool

4/27 AZN Bails on Zurampic
AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 million .... AstraZeneca has a strategy of selling certain rights to non-core medicines to help pay the bills as it invests in new drugs and copes with the loss of patent protection on a raft of former blockbusters .... Reuters

4/27 Bayer Up on Strong-Selling Xarelto and Eylea
Bayer Profit Beats Estimates as Newest Drugs Buoy Demand .... Earnings before interest, taxes, depreciation and amortization, and excluding some costs, climbed 16 percent to 3.40 billion euros ($3.83 billion) .... Bloomberg

4/27 FDA Looks at Diflucan
FDA Investigates Study Showing Yeast Infection Drug Increases Risk of Miscarriage .... The FDA is evaluating the results of a Danish study that found a possible increased risk of miscarriage with the use of Diflucan (fluconazole), a treatment for yeast infections .... Regulatory Focus

4/27 Review: Pharmacists Better Than Doctors in Managing Chronic Diseases
Pharmacists Can Manage Some Chronic Conditions Effectively .... Pharmacists may do a better job than doctors helping chronically ill patients manage their blood pressure, cholesterol and blood sugar levels if they're allowed to direct people's health care .... HealthDay

4/27 NY AG Forces Coverage for Hep C Drugs for All
New York Insurers to Change Coverage of Hepatitis C Drugs .... Deal requires seven insurers to cover the drugs for most patients with commercial insurance plans .... WSJ

4/27 Isotretinoin Warnings Often Ignored
Women using popular acne drug aren't following advice to avoid pregnancy .... Of the nearly 60,000 women who received isotretinoin, as many as 55 percent had not tried other, less dangerous acne drugs first .... Reuters

4/27 Inter Partes Review Decision May Disappoint Pharma
Supreme Court skeptical in case backed by drug makers .... The case in question focused on the Obama administration's rules for a new process to review patents. Drug makers, supporting the plaintiffs, are urging the court to change that process, which right now makes it easier to invalidate the patents that are crucial to their business. .... Stat

4/27 Pundits Give Eteplirsen 10% Chance of Approval this Go-Round
Slim Sarepta Hopes Rest With Top FDA Official .... Janet Woodcock, the director of the FDA's Center for Drug Evaluation and Research, was the most senior FDA official who attended the advisory committee meeting in Hyattsville, Md., outside Washington D.C., and she made the most supportive comments among her colleagues about the drug, eteplirsen .... Barrons

4/27 New Drug Combo for COPD
FDA Approves Bevespi Aerosphere for Patients With COPD .... Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol is the only long-acting dual bronchodilator delivered through a pressurized metered-dose inhaler. .... PTCommunity

4/27 Internet Drug News Fast Takes:
'A' to 'F': Leapfrog grades 2,571 hospitals on safety
Advisory Board Daily Briefing
Weight loss may limit diabetes-related brain changes
FDA to Massachusetts Group Home: Stop Shocking Disabled Residents
Researchers find four supplements that boost efficacy of antidepressants
Drug Store News

Fast Takes
More evidence links Nexium, similar heartburn drugs to serious kidney problems
Why Joseph Papa Left Perrigo for Valeant

4/26 FDA Panel Rejects Sarepta Muscular Dystrophy Drug
- Final decision due May 26; FDA usually follows panel vote but not always
UPDATE 2-U.S. panel: Sarepta Duchenne drug not proven effective … panel voted 7-3, with three abstentions, that the clinical trial of 12 patients did not provide substantial evidence the drug was effective for muscular dystrophy patients with a specific genetic mutation …[Reuters]
Votes by FDA drug panel dim hopes of fast approval of Duchenne drug … If the drug is rejected next month, the Cambridge-based company will likely have to wait until early next year at the earliest to reapply, and possibly until early 2018 …[Bizjournals]

Sarepta Decision: Desperate Parents And Patients Try To Sway FDA Panel
- Panel [see above] not moved by emotional pleas
FDA panel votes against Sarepta's drug for Duchenne muscular dystrophy … "FDA, please don't let me die early,"… easily one of the most politically charged FDA advisory panel meetings held for a new drug approval. advocacy pressure of the sort that I've not seen since the days of HIV and AIDS… [Pharmalot]

Novartis CEO: Share Of Voice Paradigm Is Dead; Payers Make The Market
- 10,000 of the best drug reps in the world no match for PBMs' ability to limit access
Novartis CEO: The racehorse drug launch is over in the U.S. … insurers are twisting arms for formulary positioning and erecting prior authorization hurdles to limit coverage… not going to see the hockey-stick shape we had in the 90s and 2000s with thousands of sales reps in the US … model has changed and it will take longer …[ Fierce Pharma]

Daiichi Downsizing Continues
Daiichi caps layoffs drive by melding NJ ops into one smaller HQ … After a rash of layoffs in its U.S. operations, Japanese drugmaker Daiichi Sankyo plans to consolidate its R&D and commercial operations in a new facility in Basking Ridge, NJ … part of the Japan-based company's retrenchment worldwide …[Fierce Pharma]

Boehringer Diabetes Business Booming; Diabetes Pill Jardiance®
(empagliflozin) Seen As Growth Engine
Boehringer sees turbocharged diabetes unit driving future growth … 49% growth for the diabetes business in currency-adjusted terms … Jardiance still has plenty of room to grow. For one, its makers expect to see a boost when the FDA approves the addition of the CV study data to the drug's label … [Fierce Pharma]
Boehringer Factoid:  Boehringer Ingelheim is one of the last family owned major pharmaceutical companies..  It was run by family members until 2015 when Boehringer appointed its first non-family CEO in 25 years.

Novartis In Talks To Unload $14 Billion In Roche Stock
Novartis could refuel M&A machine with $14 billion Roche stake sale …  built up its one-third stake in Roche's voting stock (RO.S) between 2001 and 2003 under former chairman and CEO Daniel Vasella, as a basis for a possible merger that never happened. … [Reuters]
Novartis/Roche: When a Separation Makes Sense for Everyone … lagged behind the European sector recently, thanks to problems in eye-care business Alcon and a slow launch for new drug Entresto …[WSJ]

Germany Plays Hardball With Drugmakers
- Some drumakers pull out rather than submit to strict price controls
Germany Is New Battlefield for Drugmakers Facing Price Scrutiny … Novo Nordisk, Bayer pulled key new drugs from the nation … emerging as a new front in the battle on drug pricing for pharmaceutical companies already engaged in skirmishes with U.S. health insurers and legislators …[Bloomberg]

Fast Takes
Sanofi lowers price of Jevtana after threat from British National Health Servic
Pharma Times
Study: No suicide risk for anti-smoking pills Chantix, Zyban
What Drug Ads Don't Say
NYT Sunday Review
The Dangers of 'Polypharmacy,' the Ever-Mounting Pile of Pills
China Eases Path for Foreign Drugmakers' Hepatitis C Treatments

Anti-Rejection Drug May Help Rare Seizure Disorder
Everolimus May Have Activity in Seizure Disorder … Drug reduced seizure frequency in tuberous sclerosis compared with placebo … larger proportion of patients also had at least a 50% reduction in seizures … opens the door to the question of whether everolimus could be useful in other seizure disorders …[Medpage Today]

Large Price Increases In List Prices For Drugs Are Norm
- Few people pay sticker price, so actual price increass are hard to figure out
More drug makers are taking hefty price hikes on more drugs … Johnson & Johnson took cumulative price hikes on more than a dozen drugs ranging from 5 percent to 28 percent …  Celgene increased price tags between 10.3 percent and 27.9 percent … [Pharmalot]

Remicade Biosim?  We Ain't Afraid  Of That
- JNJ feels its legal team, brand insistance can stave off knockoffs
J&J pooh-poohs threat from Remicade biosim this year …  giant doesn't expect the newcomer--Inflectra, a med from Celltrion and Pfizer's Hospira--to hurt Remicade's U.S. sales in 2016 … after Inflectra's [biosim Remicade] FDA approval, he expects the drug will hit the market at about 20% to 30% below Remicade's price …[Fierce Pharma]
Editorial Note: The pharma lobby will not be able to stave of biosimilar therapeutic substitution for ever.  The day will come. It's a question of whose lobby is stronger - pharma or PBM.

Valeant: Come To Pappa; New CEO In Wings
Valeant Finalizing Contract With Perrigo's Joseph Papa as Next CEO … sticking point as the Perrigo board hasn't said whether it would allow Mr. Papa to void a noncompete clause in his contract … industry experience with pharmaceutical companies such as Perrigo and wholesalers such as Cardinal Health …[WSJ]
Valeant close to announcing Perrigo's Papa as new CEO …[Fierce Pharma]

ObamaCare Enrollment Dives As New Customers Don't Pay;
- Premiums expected to rise sharply
ObamaCare Enrollment Dives As New Customers Don't Pay … expects premiums to jump even more this year than last year … In Virginia, the first state where insurers have filed their rate-hike plans for 2017, ObamaCare participants are asking for a nearly 18% premium hike, on average …[Investors Business Daily]

Vaccines = Pharma's Huge Cash Cow
Vaccines are among big pharma's best-selling products … several factors driving this growth. One is the expansion of immunisation programmes in newly industrialised countries such as China … With children already extensively vaccinated in the developed world, much of the industry's focus has turned to older age groups …[FT]

4/22 Difficult Prospects for Eteplirsen as Reviewers Remain Skeptical
Sarepta shares sink as FDA staff stay sour on muscle drug .... U.S. FDA staff reviewers stuck by their negative assessment of Sarepta Therapeutics's rare muscle disorder drug, further diminishing its chances of approval and wiping out nearly half of the company's value .... Reuters

4/22 Sarepta Just Doesn't Have Enough Data for FDA Consideration
The FDA's Muscular Dystrophy Debacle Shows Trying To Speed Drug Approvals Up Can Slow Them Down .... The handling of this situation reflects badly on the drug's maker, Sarepta Therapeutics, and on the FDA. It points to some very fixable flaws in our drug regulation system, many of them involving the way that the FDA communicates with the public .... Forbes/Matthew Herper

4/22 Entresto Selling Well in EU
Europe Warms to New Novartis Heart Drug Amid Glacial U.S. Sales .... Many European governments are the main purchasers of both drug and hospital treatment. Entresto reduces hospitalization rates for heart-failure patients by 20 percent .... Bloomberg

4/22 435,000 Americans Have Used Heroin in Past 30 Days (2014 Survey)
How Prescription Drugs Sparked America's Heroin Epidemic (included video) .... Most heroin users report having used prescription painkillers first. But in sheer numbers the damage from the illicit drug is still overshadowed by overdoses from prescription painkillers .... Bloomberg

4/22 Jimenez Says Slow Uptake Will Be the New Normal
Novartis chief warns of paradigm shift to slower US drug sales .... Joe Jimenez said the days of "hockey-stick" trajectories for new products were over as insurers and other US healthcare "payers" become more aggressive in controlling their drugs bills. .... Financial Times

4/22 Specialty Winners and Losers Under the Part B Drug Proposal
Part B Drug Proposal Has Winners and Losers Alike .... The change would boost Part B drug revenue for primary care physicians and others who administer relatively inexpensive drugs such as injectable steroids, antibiotics, and vitamins, while reducing revenue for specialists who administer the more expensive ones. .... Medscape [reg]

4/22 New Heads for Novartis US Division
Novartis splits U.S. honcho's job in two as current chief Christi Shaw steps down .... Novartis credited Shaw with the fast uptake of its new psoriasis med Cosentyx, which has quickly outpaced the company's own expectations. .... Fierce Pharma

4/22 BI Back in Business with Gains from Spiriva and Pradaxa
Boehringer Ingelheim returns to growth after US turnaround .... The turnaround follows a 2014 that was, by its own admission, 'intense and challenging' and during which sales fell more that 5% as it felt the bite of difficult conditions in the US. Chief among these were US healthcare reforms, the severe spending cuts that followed and consolidation within the US insurance industry .... PM LiVE

4/22 Biogen Weighing Value of Tecidera DTC Campaign
Biogen turned to DTC to address 'low awareness' of MS drug .... The ad "did succeed" in raising awareness about Tecfidera even though the drug's sales missed analysts' estimates for the quarter. Tecfidera brought in sales of $744 million for the first quarter of 2016, missing analysts estimates of $750 million, however sales are still up 12% from the $648 million the drug brought in during the first quarter of 2015 .... MM&M

4/22 Research Points Way to Better Flu Vaccine
Study finds factors that may influence influenza vaccine effectiveness .... Higher levels of antibody against flu surface protein neuraminidase were a better predictor of protection against flu infection and its unpleasant side effects than antibodies against hemagglutinin, the traditional target .... Medical Xpress

4/22 Internet Drug News Fast Takes:
Pills That Deliver Injection-Only Drugs
At Teaching Hospitals, Aggressive Screening May Lead To Medicare Penalties
Kaiser Health News
AbbVie gets option on early Argenx cancer drug for $40 million
How Things Get Done In Washington: Insights From 23 Former CMS Leaders
Health Affairs
Allergan's new $85M buyout adds a cosmetic drug to a growing portfolio
Fierce Biotech

4/21 MedPAC — One of the Most Influential Groups in Washington — Proposes Huge Shift in Catastropic Coverage in Part D
Panel Would Make Insurers Help Contain Rising Drug Costs .... The government currently reimburses insurers for 80 percent of a Medicare beneficiary's drug costs exceeding a certain "catastrophic" level — roughly $7,500 this year. The Medicare Payment Advisory Commission voted this month to recommend that Congress cut the federal share of catastrophic drug costs to 20 percent. .... NY Times

4/21 A Big Nothing — PCSK9 Inhibitors Selling Poorly
Breakthrough cholesterol drugs fizzle amid price pushback .... Caught between skeptical doctors and cost-conscious insurers, the drugs have barely sold. Sanofi reported a meager $10 million from Praluent in the last quarter, which it co-markets with Regeneron Pharmaceuticals. Amgen declined to break out Repatha sales .... AP

4/21 A Theory Why Anticholinergics Could Cause Cognitive Impairment
Common medicines tied to changes in the brain .... Brain scans of people who used anticholinergic drugs showed lower levels of glucose processing in the brain — an indicator of brain activity — in a region of the brain associated with memory that's also affected early in the course of Alzheimer's disease .... Reuters

4/21 Allergan Readies Big TV Promo Push for $3000–6000 Double-Chin Treatment
The Makers of Botox Are Pushing a Cure for Your Double Chin .... The active ingredient in Kybella, deoxycholic acid, is a form of bile that destroys fat cells in the digestive tract. It turns out that the stuff does the same in the chin. The treatment involves 20 to 30 tiny injections by a doctor, with care to avoid the nerves and major blood vessels running under the jawline .... Bloomberg

4/21 [Recommended]: Video on Dr. Steve Rosenberg of NIH, Pioneer of Immunotherapy
The Doctor Who Started a Cancer Treatment Revolution .... Back in the 1970s, Dr. Steve Rosenberg invented a new field of cancer treatment: immunotherapy, the harnessing of the body's own immune system to fight tumors. Today, he's using cutting-edge gene-editing techniques to help turn immunotherapy into the most promising cancer killer of our time. .... Bloomberg (autoplay video)

4/21 Payers Hate Expensive Drug Surprises
Insurers, Drugmakers Want to Exchange Info on Specialty Drugs .... New drugs often hit the market after insurers have set their rates for the year. They say they aren't able to plan for the new drugs ahead of time, which means either the insurance plans or the patients have to pay the price. The problem is on insurers' minds now because they are in the process of setting their rates for next year. .... Morning Consult

4/21 Ibrance Extends PFS; Numbers to Come at ASCO
Data back efficacy of Pfizer's breast cancer drug Ibrance .... Top-line data from the Phase III PALOMA-2 trial show that Pfizer’s Ibrance plus letrozole boosted progression-free survival (PFS) in certain patients with breast cancer .... Pharma Times

4/21 Patients of All Ages at Risk for Trastuzumab-Related Cardiac Effects, Not Just Older Pts
Breast cancer drug Herceptin increases heart damage risk .... Among women treated with anthracyclines followed by trastuzumab, 6.6 percent had a major cardiac event -- four times higher than patients receiving other types of chemotherapy. For patients treated with trastuzumab with nonanthracycline chemotherapy, 5.1 percent had a major cardiac incident, which is 1.76 times higher than the group treated with other chemotherapy .... UPI

4/21 Feds Going After Profits in Patent Deals
FTC Ramping Up Use of Disgorgement in Pay For Delay Cases .... Historically, the Federal Trade Commission has sought disgorgement mostly in consumer protection cases but hasn't frequently sought it on the antitrust side .... Bloomberg BNA

4/21 Drug Overdoses, Liver Disease and Suicide Main Causes of Mortality Trend
White Americans Are Dying Younger as Drug and Alcohol Abuse Rises .... The new federal data, drawn from all deaths recorded in the country in 2014, showed that life expectancy for whites dropped to 78.8 years in 2014 from 78.9 in 2013. Men and women had declines, but because of statistical rounding, the decline did not appear as sharp among men .... NY Times

4/21 Internet Drug News Fast Takes:
Aggressive 'mini-stroke' therapy may cut serious stroke risk by half
Novartis' Afinitor reduces seizures in Tuberous Sclerosis Complex patients
Pharma Times
BMS Opdivo extends survival in head and neck cancer trial
Pharma Times
Muscular Dystrophy Treatment Deflazacort Succeeds in Late-Stage Trial
P&T Community
Diabetes Drug That Also Treats Obesity Could Make Billions

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 4/24/16

If you feel that your intellectual property being infringed
e-mail the webmaster and we will remove the content. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions. 

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!